California Paraquat Phase-Out Highlights Parkinson's Risks but Leaves National Policy Gap
California’s paraquat ban rests on repeated observational associations with Parkinson’s but leaves federal policy and substitution questions unresolved. Evidence quality is moderate: consistent dose-response signals across human studies, yet limited by confounding and lack of randomized exposure data. Further prospective cohorts with biomarker confirmation are required.
California’s Department of Pesticide Regulation announced the ban following review of exposure data showing elevated Parkinson’s incidence among applicators. Observational cohorts report relative risks of 2.0–2.5 after adjustment for age and smoking, though absolute incidence remains low at roughly 20 additional cases per 100,000 exposed workers annually. The decision aligns with earlier restrictions in the EU and China but diverges from EPA’s 2021 re-registration that required only enhanced labeling.
Meta-analyses in journals such as Environmental Health Perspectives and Movement Disorders have pooled case-control and cohort studies, consistently finding dose-response gradients tied to cumulative lifetime exposure. These designs cannot exclude residual confounding from other pesticides or rural lifestyle factors, yet the biological plausibility is strengthened by paraquat’s induction of oxidative stress and alpha-synuclein aggregation in rodent models. Farmers counter that no equally effective, low-cost alternative exists for certain broadleaf weeds in almonds and cotton.
The policy leaves interstate commerce and federal tolerances untouched, creating enforcement challenges for produce crossing state lines. Next steps include accelerated registration reviews for alternatives such as glufosinate and expanded biomonitoring of former paraquat users to quantify latency periods between exposure and diagnosis.
California DPR: annual paraquat use will fall below 50,000 pounds statewide by end of 2027.
Sources (3)
- [1]Primary Source(https://www.cdpr.ca.gov/docs/registration/paraquat_phaseout_2026.pdf)
- [2]Supporting Source(https://jamanetwork.com/journals/jamaneurology/fullarticle/2789012)
- [3]Supporting Source(https://ehp.niehs.nih.gov/doi/10.1289/EHP10803)